| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P2093 | author name string | Qin Li | |
| Yun Xu | |||
| Cai-Xia Guo | |||
| Ya-Qing Huang | |||
| Xi-Ping Jiang | |||
| Xiao-Hui Rui | |||
| P2860 | cites work | Chemotherapy of ovarian cancer in elderly patients | Q26771397 |
| Comparative efficacy and tolerability of three treatments in old people with osteoporotic vertebral compression fracture: a network meta-analysis and systematic review | Q27026392 | ||
| Characterization of BRCA1 and BRCA2 mutations in a large United States sample | Q28383993 | ||
| A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. | Q33387755 | ||
| Retrospective multicentre study of carboplatin monotherapy for clinical stage I seminoma | Q33394656 | ||
| Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer | Q85054058 | ||
| Clinical study on carboplatin for treating pediatric patients with Wilms tumors. | Q33417678 | ||
| Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial | Q33419460 | ||
| No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data | Q33436401 | ||
| Simultaneous comparison of multiple treatments: combining direct and indirect evidence. | Q34081552 | ||
| Antitumor carboplatin is more toxic in tumor cells when photoactivated: enhanced DNA binding. | Q34283782 | ||
| Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. | Q34552660 | ||
| Risk factors for ovarian cancer: an overview with emphasis on hormonal factors | Q34764768 | ||
| Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers | Q34798269 | ||
| Graphical tools for network meta-analysis in STATA. | Q35009612 | ||
| Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy | Q35561845 | ||
| Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients | Q36166812 | ||
| Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy | Q36338785 | ||
| Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 | ||
| Recent progress in the diagnosis and treatment of ovarian cancer | Q36622857 | ||
| Pegylated liposomal doxorubicin in ovarian cancer | Q36718020 | ||
| Assessing the quality of randomized controlled urological trials conducted by korean medical institutions | Q36859804 | ||
| Evaluation of networks of randomized trials | Q36966424 | ||
| A Bayesian network meta-analysis on comparisons of enamel matrix derivatives, guided tissue regeneration and their combination therapies. | Q37990925 | ||
| PARP inhibitors in ovarian cancer: current status and future promise | Q38194324 | ||
| Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option | Q38201442 | ||
| Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. | Q38405627 | ||
| Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. | Q38727450 | ||
| Camptothecin and topotecan inhibit adipocyte differentiation by inducing degradation of PPARγ. | Q38863512 | ||
| Epirubicin directly promotes hepatitis B virus (HBV) replication in stable HBV-expressing cell lines: a novel mechanism of HBV reactivation following anticancer chemotherapy | Q39021147 | ||
| Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. | Q41897007 | ||
| Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study. | Q42951134 | ||
| Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GI | Q44117882 | ||
| First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin | Q44680330 | ||
| Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial | Q44735204 | ||
| Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial | Q45178810 | ||
| Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer | Q46445233 | ||
| Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer S | Q46966646 | ||
| Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life | Q47943882 | ||
| First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. | Q48449663 | ||
| Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. | Q53144473 | ||
| Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. | Q53251965 | ||
| A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. | Q53298171 | ||
| Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. | Q53301937 | ||
| A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer | Q80473363 | ||
| Topotecan plus carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a meta-analysis of randomized controlled trials | Q84041649 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 19125-19136 | |
| P577 | publication date | 2016-11-09 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer | |
| P478 | volume | 8 |
| Q41709594 | Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis | cites work | P2860 |
Search more.